Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444357 | 0.88 | SQOR (0.37) | SQORADORA2AADORA1KDM4ENPC1 | |
| SCHEMBL6443675 | 0.83 | MGMT (0.48) | SQORADORA2AADORA1KDM4E | |
| SCHEMBL5131727 | 0.82 | ADORA2A (0.52) | SQORADORA2AADORA1KDM4E | |
| SCHEMBL5131947 | 0.82 | ADORA1 (0.50) | ADORA2AADORA1KDM4E | |
| SCHEMBL6444489 | 0.82 | ADORA2A (0.40) | SQORADORA2AADORA1KDM4EGABRA1 | |
| SCHEMBL6441608 | 0.81 | ADORA2A (0.41) | SQORADORA2AADORA1KDM4EGABRA1 | |
| SCHEMBL5131348 | 0.81 | ADORA2A (0.42) | SQORADORA2AADORA1GABRA1GABRG2 | |
| SCHEMBL6441503 | 0.81 | ADORA2A (0.42) | SQORADORA2AADORA1GABRA1GABRG2 | |
| SCHEMBL7151940 | 0.80 | SQOR (0.55) | SQORADORA2AADORA1KDM4EPIK3CD | |
| SCHEMBL5040238 | 0.79 | SQOR (0.37) | SQORADORA2AADORA1GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261327-B1 | ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | EP | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | SQOR 798/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.